TYRA vs NOAH Comparison

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Noah Holdings Ltd is a wealth management service provider. It focuses on wealth investment and asset allocation services for high-net-worth individuals and enterprises in China. The company operates through three segments: wealth management, asset management, and other business. Its product offerings consisting of over-the-counter wealth management and OTC asset management products and mutual fund products. The portfolio of the group mostly includes fixed income products, private equity funds and securities investment funds. Majority of the firm revenue is generated through one-time commissions and recurring service fees paid by third-party product providers.